Dr. Keedy on Regorafenib for the Treatment of GIST
Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the use of regorafenib for the treatment of patients with GIST.
Once patients progressed through imatinib and sunitinib, they had no FDA-approved options to treat their GIST. Many of these patients were treated off-label and by community doctors, rather than seek treatment on a clinical trial at an academic center.
Regorafenib provides an effective third-line drug, but Keedy says patients still are not coming onto clinical trials.